Download PDF

1. Company Snapshot

1.a. Company Description

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers.


It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury.The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition.


It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department.The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases.It markets its products and services through its direct sales force and a network of distributors in the United States and internationally.


The company was founded in 1976 and is headquartered in New York, New York.

Show Full description

1.b. Last Insights on ENZ

Enzo Biochem's recent performance was negatively driven by a first-quarter fiscal 2025 quarterly loss and revenue drop across regions, amid challenges in the life sciences tools market. The company also received a notice of non-compliance with New York Stock Exchange listing rules due to low market capitalization, stockholder's equity, and average closing stock price. These issues limit the company's liquidity and increase the risk of delisting, which could further impact investor confidence and potentially lead to a significant loss of value for shareholders.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction

Jun -24

Source: globenewswire.com

Card image cap

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

Jun -16

Source: globenewswire.com

Card image cap

Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction

Apr -22

Source: globenewswire.com

Card image cap

The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment

Apr -16

Source: zacks.com

Card image cap

Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

Mar -28

Source: globenewswire.com

Card image cap

Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

Mar -17

Source: globenewswire.com

Card image cap

Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules

Jan -14

Source: globenewswire.com

Card image cap

ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges

Dec -19

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.10%)

6. Segments

Life Sciences Products

Expected Growth: 8.1%

Growing demand for genomics, proteomics, and cellular analysis in disease diagnosis and scientific discovery drives the growth of Enzo Biochem's Life Sciences Products. Increasing adoption of precision medicine, advancements in biotechnology, and rising investments in life sciences research fuel the market growth.

7. Detailed Products

AMPIPROBE

A molecular diagnostic platform that enables the detection of nucleic acid sequences

LATERAL FLOW

A point-of-care diagnostic platform for the detection of infectious diseases

ENZYMES

A range of enzymes used in molecular biology applications

LABELING KITS

Kits for labeling nucleic acids with fluorescent or radioactive labels

CLIA LABORATORIES

Clinical laboratory testing services for infectious diseases, genetics, and oncology

MOLECULAR DIAGNOSTICS

Molecular diagnostic tests for infectious diseases, genetics, and oncology

8. Enzo Biochem, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Enzo Biochem, Inc. is moderate due to the presence of alternative products and services in the life sciences and biotechnology industries.

Bargaining Power Of Customers

The bargaining power of customers for Enzo Biochem, Inc. is low due to the company's strong brand reputation and the lack of switching options for customers.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Enzo Biochem, Inc. is moderate due to the presence of multiple suppliers in the market and the company's dependence on a few key suppliers.

Threat Of New Entrants

The threat of new entrants for Enzo Biochem, Inc. is high due to the low barriers to entry in the life sciences and biotechnology industries and the presence of venture capital funding for startups.

Intensity Of Rivalry

The intensity of rivalry for Enzo Biochem, Inc. is high due to the presence of multiple competitors in the market and the high stakes of competition in the life sciences and biotechnology industries.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 8.19%
Debt Cost 3.95%
Equity Weight 91.81%
Equity Cost 7.72%
WACC 7.41%
Leverage 8.92%

11. Quality Control: Enzo Biochem, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Neuronetics

A-Score: 4.4/10

Value: 7.2

Growth: 4.0

Quality: 3.5

Yield: 0.0

Momentum: 10.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Psychemedics

A-Score: 4.2/10

Value: 7.1

Growth: 1.7

Quality: 4.1

Yield: 2.0

Momentum: 7.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Enzo Biochem

A-Score: 3.6/10

Value: 8.8

Growth: 1.0

Quality: 3.7

Yield: 7.0

Momentum: 0.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
NeoGenomics

A-Score: 3.2/10

Value: 9.6

Growth: 3.2

Quality: 3.4

Yield: 0.0

Momentum: 1.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Standard BioTools

A-Score: 3.1/10

Value: 7.8

Growth: 3.6

Quality: 4.3

Yield: 0.0

Momentum: 1.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Myriad Genetics

A-Score: 2.9/10

Value: 8.6

Growth: 1.9

Quality: 4.8

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.31$

Current Price

0.31$

Potential

-0.00%

Expected Cash-Flows